Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response.
Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response.
复制标题
DOI：
10.4172/1948-5956.1000373
复制
发表时间：
2015-11
期刊：
影响因子：
--
通讯作者：
Almasan A
中科院分区：
文献类型：
--
作者：
Singh V;Gupta D;Almasan A
利妥昔单抗是一种革命性和有效的靶向CD 20的单克隆抗体。虽然，它被广泛用于淋巴瘤治疗，许多患者已经受益。然而，由于细胞表面上的低水平的CD 20表达和/或可用性，大量患者是难治性的或对当前疗法产生抗性。因此，开发具有强大细胞杀伤能力和增强细胞表面CD 20水平的新型抗CD 20 mAb可能会开发淋巴瘤治疗。在这种情况下，我们总结了最近开发的抗CD 20的单克隆抗体和能够诱导CD 20表达的化合物。我们还提供了关于在体外使用辐射和抗CD 20 mAb的组合策略的信息。然而，它需要通过严格的临床前和临床试验来确定。我们希望这篇综述将有助于目前在免疫治疗或放射免疫治疗领域的研究。
Rituximab has been revolutionized and validated CD20 targeting monoclonal antibody. Although, it is widely used for lymphoma therapy and many patients have been benefited. However significant numbers of patients are refractory or developed resistance to current therapies due to low level of CD20 expression and/or availability on cells surface. Thus development of novel anti-CD20 mAbs with great cell killing ability and enhance CD20 levels on cell surface can potentially exploit lymphoma therapy. In this scenario, we are summarizing the recently developed mAbs against CD20 and compounds that have ability to induce CD20 expression at significant level. We also are providing information regarding combination strategy for use of radiation and anti-CD20 mAbs in vitro. However, it will need to be determined by rigorous at pre-clinical and clinic testing. We hope this review will be beneficial for current research in the area of immunotherapy or radio-immunotherapy.